Is Angiotensin 1-7 (Ang1-7) supplement Safe with Enalapril?
Free · No account · based on published sources including NIH ODS, FDA drug labels, and peer-reviewed literature
Be aware that background enalapril therapy reduces the Ang-II pool by 11–20-fold, which proportionately decreases Ang1-7 and Ang1-5 peptide abundance; if Ang1-7 supplementation is intended to raise protective angiotensin peptide levels, an ARB background therapy may be more compatible as it increases the Ang1-7 pool by 160–260%.
Why this interaction occurs
Clinical data showed ACEI therapy (enalapril) suppressed the RAS substrate pool (Ang-II), leading to proportionate reductions in downstream Ang1-7 and Ang1-5 peptides, potentially limiting the therapeutic utility of exogenous Ang1-7 supplementation in this drug context.
Evidence
Evidence level: limited.
Data source
PubMed - PMID 39837966
Reported safety data
The FDA’s adverse event reporting system (FAERS) has received 61,312 reports mentioning Enalapril. This reflects reported cases involving the medication in general — not confirmed causation, and not specific to the Enalapril + supplement combination on this page.
FAERS reports are voluntary and cannot prove that a drug caused an event. Do not use report counts to assess the safety of this specific drug-supplement pair.
Frequently asked questions
Related interactions
All Angiotensin 1-7 (Ang1-7) supplement interactions → · All Enalapril interactions →
Already checked this one — check your whole list
Educational only — not medical advice.
Always confirm with your doctor or pharmacist.